119-hres685

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 685 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
H. RES. 685

Expressing support for testing for antiphospholipid syndrome

    (APS) as a 
 standard part of prenatal screening, and for other purposes.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 September 9, 2025

Mrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen, 
 Mrs. Hinson, Ms. Adams, Mrs. Cherfilus-McCormick, and Mr. Landsman) 
submitted the following resolution; which was referred to the Committee 
 on Energy and Commerce

_______________________________________________________________________

 RESOLUTION

Expressing support for testing for antiphospholipid syndrome

    (APS) as a 
 standard part of prenatal screening, and for other purposes.

Whereas antiphospholipid syndrome

    (APS) is a condition in which the immune 
 system of an individual mistakenly produces antibodies that increase the 
 risk of blood clots;
Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy 
 complications;
Whereas professional medical associations and guideline-setting bodies do not 
 recommend testing for APS as a standard part of prenatal screening;
Whereas professional medical associations and guideline-setting bodies recommend 
 testing for APS only if a woman has an unexplained fetal loss after 10 
 weeks or 3 or more unexplained embryonic losses

    (miscarriages) ;
Whereas APS is responsible for about 15 percent of recurrent pregnancy losses;
Whereas the total number of miscarriages caused by APS is unknown because it is 
 not tested as part of normal prenatal screening;
Whereas APS can be detected by a blood test and treated by blood thinners; and
Whereas testing for APS during normal prenatal screening can save babies and 
 reduce grief for women and families: Now, therefore, be it
 Resolved, That the House of Representatives--

    (1) supports testing for antiphospholipid syndrome

    (APS) as 
 a standard part of prenatal screening; and

    (2) calls upon professional medical associations and 
 guideline-setting bodies to update their recommendations to 
 include testing for APS as a standard part of prenatal 
 screening.
 <all>